It is made available under a CC-BY 4.0 International license .

1	
2	
3	
4	A 4-year review of amniocentesis at a tertiary hospital in Ethiopia: an experience
6	
7	
8	Haile G. Mekuria ¹ *, Hilkiah K. Suga ^{2†} , Gadise Bekele ³
9	
10 11	¹ Department of Obstetrics and Gynecology, Myungsung Medical College/MCM Comprehensive Specialized Hospital, Addis Ababa, Ethiopia
12	² Department of Research, Blue Health Medical Consultancy, Addis Ababa, Ethiopia
13 14	³ Department of Biostatistics, Addis Continental Institute of Public Health, Addis Ababa, Ethiopia
15	
16	*First author
17	⁺ Corresponding author: <u>hilkms@gmail.com</u>

It is made available under a CC-BY 4.0 International license .

18 Abstract

Background: Amniocentesis is a technique for withdrawing amniotic fluid from the uterine cavity using a needle via a trans-abdominal approach. It has multiple diagnostic and therapeutic uses such as prenatal genetic studies and amnioreduction for polyhydramnios. The commonest indications are advanced maternal age and increased risk on maternal serum screening. The objective of this study is to review the common indications, outcomes and complications of amniocentesis at a tertiary hospital in Ethiopia.

Methods: A retrospective cross-sectional study was conducted at a tertiary hospital in Ethiopia. Data was collected from the Fetomaternal division's log records and follow-up charts during the time period of 2019 to 2022. All records of patients who had amniocentesis done were included in the study. Socio-demographic information and obstetric history and variables related to the procedures were retrieved. Descriptive statistics was done using the software IBM Statistical Package for Social Sciences (SPSS) version 25.

Results: A total of 35 patients' records were reviewed. The mean maternal age was 32
years (range, 19 – 43 years). The mean gestational age was 20.9 weeks (SD ± 2.2).
The commonest indications for amniocentesis were previous history of Down syndrome
(11%), advanced maternal age (9%) and QUAD 1:200 for Down syndrome (6%).
Karyotype test was done in 29 of the 35 amniocentesis cases which was normal in 72%
of the cases, 17% had Trisomy-21 and 11% had Trisomy-18. Fifty-two percent of the
pregnancy had a live full term delivery and 25% of the cases terminated the pregnancy.

40 Conclusion: The most common indications for amniocentesis in Ethiopia were abnormal 41 ultrasound finding, advanced maternal age and abnormal QUAD test results. Around a 42 quarter of the genetic tests which were done after the procedure had chromosomal 43 abnormalities, from which, the majority were terminated. There was no complication 44 related to the procedure.

- 45 Keywords: amniocentesis, advanced maternal age, prenatal genetic study,
- 46 chromosomal abnormality, fetomaternal complication

It is made available under a CC-BY 4.0 International license .

47 Introduction

Amniocentesis is a technique for withdrawing amniotic fluid from the uterine cavity using a needle via a trans-abdominal approach. Amniocentesis has been widely used since it was first performed in 1956. Originally reported as a method of determining fetal sex in utero, Fuchs and Riis then hypothesized that it could be possible to diagnose chromosomal abnormalities in utero via this technique. By 1963, it had been confirmed that the karyotype of fetal and amniotic cells are identical (1 - 3).

The most common diagnostic indications for obtaining amniotic fluid are prenatal genetic studies and assessment of fetal lung maturity. Other indications include, but are not limited to, evaluation of the fetus for infection, degree of hemolytic anemia, blood or platelet type, hemoglobinopathy, and neural tube defects. Risks include spontaneous abortion, infection, needle injuries, and preterm labor (4, 5).

59 Amniocentesis is also performed as a therapeutic procedure to remove excess amniotic 60 fluid, such as in symptomatic polyhydramnios or twin-twin transfusion syndrome, or to 61 reduce volume and pressure of amniotic fluid in cases of prolapsed fetal membranes in 62 the second trimester to facilitate placement of an emergency cerclage.(6, 7)

Since the late 1960s, amniocentesis has become a widely accepted method of obtaining fetal genetic information (8). Amniocentesis for prenatal genetic studies is technically possible at any gestational age after approximately 11 weeks of gestation, but is optimally performed after 15 to 17 weeks of gestation. Procedures performed before 15 weeks (ie, early amniocentesis) are associated with higher fetal loss and complication rates, including culture failure, and should be avoided. Later procedures

It is made available under a CC-BY 4.0 International license .

can be problematic if termination of pregnancy is planned based upon abnormal results.
Although some pain is associated with amniocentesis, it is generally well tolerated
without the need for anesthesia (8, 9).

Maternal age over 35 is the most common indication for amniocentesis (10). It is conventionally performed between 16 – 24 weeks. The chances of late-onset abnormalities after 1st and 2nd-trimester ultrasound examinations are estimated at 5.5%-17% (11).

Counseling about the risk and benefit of the procedure is very important as some women may decline the procedure if they don't want to terminate the pregnancy whatever the result is. Others, even if they don't want to terminate the pregnancy, they accept the procedure to prepare themselves for the care of the baby after delivery (12).

Prenatal chromosomal microarray analysis is recommended for a patient with a fetus with one or more major structural abnormalities identified on ultrasonographic examination and who is undergoing invasive prenatal diagnosis (13).

Even though the procedure is more than 6 decades old, as far as the authors search goes, this report is the first of its kind from an experience located in the Eastern Africa. This study aims to review the common indications and outcomes of prenatal diagnostic amniocentesis and its complications at a tertiary center in Ethiopia.

87 Methods

A retrospective cross-sectional study was conducted at the Fetomaternal division,
 Department of Obstetrics and Gynecology, MCM Comprehensive Specialized Hospital,

Addis Ababa, Ethiopia. The department is one of the few in the country that gives 90 91 prenatal amniocentesis service. Data was collected from the division's log records and follow-up charts which was abstracted from 2019 to 2022. Study period was from June 92 93 1st to 30th, 2023. Records of all patients who had prenatal amniocentesis done during the timeframe were included in the study. The following variables were collected: 94 indication, maternal age, gestational age, needle size, BMI, pregnancy outcome, result 95 of the genetic test, presence of vaginal bleeding post-procedure, presence of 96 amnionitis. The procedures were carried out by the same fetomaternal specialist using 97 the same ultrasound guided techniques. IBM Statistical Package for Social Sciences 98 (SPSS) version 25 was used to compute descriptive statistics. 99

Ethical approval was obtained prior to the data collection and the investigators did not collect personal identification information of the patients.

102 Results

A total of 35 women had amniocentesis between 2019 and 2022 with the mean maternal age was 32 years (range, 19 - 43 years). The mean gestational age was 20.9 weeks (SD ± 2.2, range 17 – 25) and mean maternal BMI was 21 kg/m2 (SD ± 2.4). In 23 patients, 20 Gauge needle was used and 22 Gauge was used in the others. The needle insertion to the probe angle was perpendicular in 30 of the procedures (85%) and parallel in 5 of the procedures (15%).

109 The commonest indications were previous history of down syndrome (11%), advanced 110 maternal age (9%), cleft lip (6%), history of Recurrent pregnancy loss or RPL (6%),

It is made available under a CC-BY 4.0 International license .

hydrocephalus (6%), non-immune hydrops (6%), omphalocele (6%), QUAD 1:200 for
down syndrome (6%).

Karyotype test was done in 29 of the 35 amniocentesis cases. Karyotype results were normal in 72% of cases (21/29), Trisomy-21 in 17% (5/29) and Trisomy-18 in 11% (3/29). Almost half (52%) of the cases had a live birth, 46% (16/35) had a term delivery and 6% (2/35) had a preterm delivery. Stillbirth or miscarriage occurred in 17% (6/35), 25% (9/35) of the cases terminated the pregnancy and the outcome was not known in 6% (2/35) of the cases. Pathological ultrasonography has the highest positive detection rate (30%)

120 Discussion

Amniocentesis is generally done after the 15th gestational week with a miscarriage risk of less than 1% (14, 15). The risk of spontaneous fetal losses following amniocentesis preformed before this gestational age increases (16). Likewise, the patients in our study were between the gestational age of 17 and 25 weeks, which were under the accepted gestational age range.

Currently twenty and twenty-two gauge needles are commonly used and in this study, two-third of the procedure was done using a 20G needle. The larger needle size i.e. 20G is associated with significantly shorter duration of amniocentesis. However, there is no significant difference in the intrauterine bleeding at the insertion site and fetal loss (17, 18). Likewise, none of the patients in this study had documented intrauterine bleeding in both groups (20G vs 22G).

It is made available under a CC-BY 4.0 International license .

A study done in South East China that did a retrospective analysis on more than 4700 132 133 patients who had an amniocentesis showed the commonest indications for amniocentesis were increased risk on maternal serum screenings and advanced 134 135 maternal age. They are indications for 86% of the procedures (5). Another 5 year 136 reviews from Malaysia and China hospitals showed similar findings i.e. both indications accounted for more than half of the total procedures (19, 20). Other common indications 137 include poor obstetric history, pathological ultrasonography findings and positive results 138 139 from non-invasive prenatal testing. However, in our study, the majority of indication for amniocentesis was done due to the pathological ultrasonography findings (57% vs 12% 140 or 4%) followed by previous Down syndrome baby and increased risk on maternal 141 serum screenings, each accounted for 11% of the procedures. Advanced maternal age 142 was an indication in only 9% of cases. 143

Positive detection rate of pathological ultrasonography for chromosomal abnormalities is less than 15% (19, 20). Noninvasive prenatal DNA testing has the highest positive detection rate with greater than 40% (42% and 53%). In our study, pathological ultrasonography has the highest positive detection rate (30%).

148 Conclusion

A review of the first 5 years of amniocentesis at our center showed that the most common indication to the procedure was abnormal ultrasound finding. Advanced maternal age and abnormal QUAD test results were also among the common indications. Around a quarter of the genetic tests which were done after the procedure had chromosomal abnormalities, from which, the majority were terminated. There was

It is made available under a CC-BY 4.0 International license .

- no complication related to the procedure. Further study is required to understand more
- 155 fetomatenal complications of amniocentesis in Ethiopia.

It is made available under a CC-BY 4.0 International license .

156 Reference

- 157 (1) FUCHS F, RIIS P. Antenatal sex determination. Nature. 1956 Feb 18;177
- 158 (4503):330. doi: 10.1038/177330a0. PMID: 13297032.

(2) Connolly KA, Eddleman KA. Amniocentesis: A contemporary review. World J Obstet
 Gynecol 2016; 5(1): 58-65 [DOI: 10.5317/wjog.v5.i1.58]

- 161 (3) Steele MW, Breg WR Jr. Chromosome analysis of human amniotic-fluid cells.
- Lancet. 1966 Feb 19;1(7434):383-5. doi: 10.1016/s0140-6736(66)91387-0. PMID:
 4159775.
- 164 (4) Bornstein E, Lenchner E, Donnenfeld A, Barnhard Y, Seubert D, Divon MY.
- Advanced maternal age as a sole indication for genetic amniocentesis; risk-benefit
- analysis based on a large database reflecting the current common practice. J Perinat
- 167 Med. 2009;37(2):99-102. doi: 10.1515/JPM.2009.032. PMID: 18999912.
- (5) Tao H, Xiao J, Yang C, Wang J, Tang Y, Guo C, Wang J. Retrospective analysis of
- 169 4761 cases who underwent amniocentesis in southeast China. J Obstet Gynaecol. 2018
- 170 Jan;38(1):38-41. doi: 10.1080/01443615.2017.1326887. Epub 2017 Aug 1. PMID:
- 171 **28764586**.
- (6) Erfani H, Diaz-Rodriguez GE, Aalipour S, Nassr A, Rezaei A, Gandhi M, Mendez-
- 173 Figueroa H, Aagaard KM, Shamshirsaz AA. Amnioreduction in cases of
- 174 polyhydramnios: Indications and outcomes in singleton pregnancies without fetal
- interventions. Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:126-128. doi:
- 176 10.1016/j.ejogrb.2019.05.019. Epub 2019 May 19. PMID: 31160132.
- (7) Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org;
- 178 Dashe JS, Pressman EK, Hibbard JU. SMFM Consult Series #46: Evaluation and
- management of polyhydramnios. Am J Obstet Gynecol. 2018 Oct;219(4):B2-B8. doi:
- 180 10.1016/j.ajog.2018.07.016. Epub 2018 Jul 23. PMID: 30048635.
- (8) Daum H, Ben David A, Nadjari M, Zenvirt S, Helman S, Yanai N, Meiner V, Yagel S,
 Frumkin A, Shkedi Rafid S; collaborating authors. Role of late amniocentesis in the era
 of modern genomic technologies. Ultrasound Obstet Gynecol. 2019 May;53(5):676-685.
 doi: 10.1002/uog.20113. Epub 2019 Apr 12. PMID: 30155922.
- (9) Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. Obstet
 Gynecol. 2016 May;127(5):e108-e122. doi: 10.1097/AOG.00000000001405. PMID:
 26938573.

- (10) Papp C, Papp Z. Chorionic villus sampling and amniocentesis: what are the risks in
- current practice? Curr Opin Obstet Gynecol. 2003 Apr;15(2):159-65. doi:
- 190 10.1097/00001703-200304000-00011. PMID: 12634608.
- 191 (11) Quinlan MP. Amniocentesis: indications and risks. Virtual Mentor. 2008 May
- 192 1;10(5):304-6. doi: 10.1001/virtualmentor.2008.10.5.cprl1-0805. PMID: 23211983.
- 193 (12) Bardin R, Hadar E, Haizler-Cohen L, Gabbay-Benziv R, Meizner I, Kahana S,
- 194 Yeshaya J, Yacobson S, Cohen-Vig L, Agmon-Fishman I, Basel-Vanagaite L, Maya I.
- 195 Cytogenetic analysis in fetuses with late onset abnormal sonographic findings. J Perinat
- 196 Med. 2018 Nov 27;46(9):975-982. doi: 10.1515/jpm-2017-0071. PMID: 28915119.
- (13) Committee on Genetics and the Society for Maternal-Fetal Medicine. Committee
- 198 Opinion No.682: Microarrays and Next-Generation Sequencing Technology: The Use of
- Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. Obstet Gynecol.
- 200 2016 Dec;128(6):e262-e268. doi: 10.1097/AOG.00000000001817. PMID: 27875474.
- (14) Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the
- 202 fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year
- 203 experience. Obstet Gynecol. 2008 Mar;111(3):589-95. doi:
- 204 10.1097/AOG.0b013e318162eb53. PMID: 18310360.
- 205 (15) Salomon LJ, Sotiriadis A, Wulff CB, Odibo A, Akolekar R. Risk of miscarriage
- 206 following amniocentesis or chorionic villus sampling: systematic review of literature and
- updated meta-analysis. Ultrasound Obstet Gynecol. 2019 Oct;54(4):442-451. doi:
 10.1002/uog.20353. Epub 2019 Sep 6. PMID: 31124209.
- 209 (16) Saltvedt S, Almström H. Fetal loss rate after second trimester amniocentesis at
- different gestational age. Acta Obstet Gynecol Scand. 1999 Jan;78(1):10-4. PMID:
- 211 **9926885**.
- (17) Athanasiadis A, Petrakis P, Mikos T. Comparison of perinatal outcome after 2nd
- trimester amniocentesis using 22G and 20G needle. Hippokratia. 2017 Jan-
- 214 Mar;21(1):60. PMID: 29904263; PMCID: PMC5997025.
- (18) Athanasiadis AP, Pantazis K, Goulis DG, Chatzigeorgiou K, Vaitsi V,
- Assimakopoulos E, Tzevelekis F, Tsalikis T, Bontis JN. Comparison between 20G and
- 217 22G needle for second trimester amniocentesis in terms of technical aspects and short-
- term complications. Prenat Diagn 2009; 29: 761-765 [PMID: 19412914 DOI:
- 219 10.1002/pd.2283]
- (19) Jummaat F, Ahmad S, Mohamed Ismail NA. 5-Year review on amniocentesis and
- its maternal fetal complications. Horm Mol Biol Clin Investig. 2019 Sep

222 20;40(2):/j/hmbci.2019.40.issue-2/hmbci-2019-0006/hmbci-2019-0006.xml. doi:

223 10.1515/hmbci-2019-0006. PMID: 31539354.

(20) Liu Y, Sun XC, Lv GJ, Liu JH, Sun C, Mu K. Amniotic fluid karyotype analysis and

225 prenatal diagnosis strategy of 3117 pregnant women with amniocentesis indication. J

226 Comp Eff Res. 2023 May 31;12(6):e220168. doi: 10.57264/cer-2022-0168. Epub ahead

of print. PMID: 37256256; PMCID: PMC10402904.

228

Table 1: A five year summary of genetic test results and indications for amniocentesis at MCM Comprehensive Specialized Hospital, 2019 – 2022

Genetic test result			Number of cases	Percenta ge (denomina tor being the subtotal, %)	Percentag e (denominat or being the grand total, %)
Normal	Indication for amniocentesis	Advanced maternal	2	9.52	5.71
Raryotype		Bathological	12	57 14	34.28
			12	57.14	54.20
		findings			
		History of recurrent	1	4.76	2.86
		Previous history of MR baby	1	4.76	2.86
		Previous hx of Down Syndrome	4	19.05	11.43
		QUAD 1:200 for Down Syndrome	1	4.76	2.86
	Total		21	100	60
Trisomy 21	Indication for amniocentesis	Pathological ultrasonography findings	5	100	14.29
	Total		5	100	14.29
Trisomy	Indication for	Pathological	1	33.33	2.86
18	amniocentesis	ultrasonography			
		findings			
		History of still birth	1	33.33	2.86
		QUAD 1:10 for	1	33.33	2.86
		trisomy 18			
	Total		3	100	8.57

It is made available under a CC-BY 4.0 International license .

Not	Indication for	Advanced maternal	1	16.67	2.86
determine amniocentesis		age			
d		Pathological	2	33.33	5.71
		ultrasonography			
		findings			
		History of RPL	1	16.67	2.86
		QUAD 1:150 for Down	1	16.67	2.86
		Syndrome			
		QUAD 1:200 for Down	1	16.67	2.86
		Syndrome			
	Total		6	100	17.14
Grand total			35		100

It is made available under a CC-BY 4.0 International license .

Table 2: Pregnancy outcomes and genetic test results of women who had

amniocentesis at MCM Comprehensive Specialized Hospital, 2019 – 2022

	Genetic test result			Total		
		Normal	Trisomy	Not		
	1		18 or 21	determined		
Pregnancy	Term delivery	12	0	4		16
outcome	Preterm delivery	2	0	0		2
	Terminated	1	7	1		9
	Still birth	5	1	0		6
	Unknown	1	0	1		2
Total		21	8	6		35